SCHEMBL7204519

SCHEMBL7204519

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(Oc2ccc(Cl)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 7/20 0.43
MMP12 P39900 1/20 0.43
FPR2 P25090 5/20 0.42
PROKR1 Q8TCW9 5/20 0.42
MMP1 P03956 5/20 0.40
MMP9 P14780 2/20 0.40
ADAM17 P78536 2/20 0.40
ADAMTS4 O75173 1/20 0.40
HRH1 P35367 1/20 0.38
CCR3 P51677 1/20 0.38
EPHX2 P34913 2/20 0.38
MMP2 P08253 2/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
ACLY P53396 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200991 0.90 MMP13 (0.43) MMP13FPR2PROKR1MMP1ADAM17
SCHEMBL7202573 0.90 MMP13 (0.43) MMP13MMP12FPR2PROKR1MMP1
SCHEMBL7201546 0.90 SMN1; SMN2 (0.48) MMP13FPR2PROKR1MMP1MMP9
SCHEMBL7199648 0.90 HTR2C (0.44) MMP13FPR2PROKR1ADAM17HRH1
SCHEMBL7206963 0.89 HTR2C (0.49) MMP13FPR2PROKR1MMP1HRH1
SCHEMBL7201643 0.88 MMP13 (0.41) MMP13MMP1ADAM17EPHX2MMP2
SCHEMBL7205543 0.86 MMP13 (0.42) MMP13MMP12MMP1MMP9ADAM17
SCHEMBL7205721 0.85 MMP13 (0.45) MMP13MMP1MMP9ADAMTS4MMP2
SCHEMBL7201026 0.84 HTR2C (0.48) HRH1CCR3EPHX2
SCHEMBL7200905 0.83 MMP13 (0.58) MMP13MMP12FPR2PROKR1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP13 4/4885MMP12 27/4885FPR2 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.